Gene therapy trial aims to train immune cells to hunt blood cancer
NCT ID NCT03602612
Summary
This is an early-stage safety study testing a new type of cell therapy for adults with multiple myeloma that has not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack the cancer, and then infuse them back into the patient. The main goal is to find a safe dose and see if this approach is feasible for controlling this difficult-to-treat blood cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA, MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.